ArticleJournal for immunotherapy of cancer2026

Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318.

Hans Prenen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.